rVWF: treatment finally reaches the modern age.


In this issue of Blood, Gill et al describe the results of the first phase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorrhagic events in all patients with von Willebrand disease (VWD). 
DOI: 10.1182/blood-2015-08-664052


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics